Wen Jess Li

This study quantifies cancer stemness in prostate cancer across progression stages, showing its association with therapy resistance, poor survival, and lineage plasticity.

This study validates BCL-2 as a therapeutic target in CRPC by showing its upregulation under AR inhibition and demonstrating efficacy of BCL-2 inhibitors in preclinical and clinical models.

The paper shows that loss of ATG5 in prostate cancers leads to tumor growth by accumulating p62, suggesting ATG5 acts as a tumor suppressor in this context.

This study evaluates folate-conjugated miR-34a as a potential prostate cancer therapeutic, finding limited efficacy due to low FOLR1 expression in prostate cancer cells.